Literature DB >> 14633187

Disposition of cyclosporine after intravenous and multi-dose oral administration in cats.

M L Mehl1, A E Kyles, A L Craigmill, S Epstein, C R Gregory.   

Abstract

The aim of this study was to evaluate the disposition of cyclosporine after intravenous (i.v.) and oral administration and to evaluate single sampling times for therapeutic monitoring of cyclosporine drug concentrations in cats. Six adult male cats (clinically intact) were used. Two treatments consisting of a single i.v. cyclosporine (1 mg/kg) and multiple oral cyclosporine (3 mg/kg b.i.d p.o. for 2 weeks) doses. Whole blood cyclosporine concentrations were measured at fixed times by high performance liquid chromatography and pharmacokinetic values were calculated. Mean values for the i.v. data included AUC (7413 ng/mL.h), t1/2 distribution and elimination (0.705 and 9.7 h, respectively), Cmax (1513 ng/mL), and Vd(ss) (1.71 L/kg). Mean values for the oral data included AUC (6243 ng/mL.h), t1/2 of absorption and elimination (0.227 and 8.19 h, respectively), and Cmax (480.0 ng/mL). Bioavailability of orally administered cyclosporine was 29 and 25% on days 7 and 14 respectively. Whole blood comment cyclosporine concentration 2 h after administration (C2) better correlated with AUC on days 7 and 14 than trough plasma concentration (C12). The rate of oral cyclosporine absorption was less than expected and there was substantial individual variation. Therapeutic drug monitoring strategies for cyclosporine in cats should be re-evaluated.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14633187     DOI: 10.1046/j.1365-2885.2003.00496.x

Source DB:  PubMed          Journal:  J Vet Pharmacol Ther        ISSN: 0140-7783            Impact factor:   1.786


  3 in total

1.  A multidisciplinary evaluation of the effectiveness of cyclosporine a in dystrophic mdx mice.

Authors:  Annamaria De Luca; Beatrice Nico; Antonella Liantonio; Maria Paola Didonna; Bodvael Fraysse; Sabata Pierno; Rosa Burdi; Domenica Mangieri; Jean-François Rolland; Claudia Camerino; Alberta Zallone; Paolo Confalonieri; Francesca Andreetta; Elisa Arnoldi; Isabelle Courdier-Fruh; Josef P Magyar; Antonio Frigeri; Michela Pisoni; Maria Svelto; Diana Conte Camerino
Journal:  Am J Pathol       Date:  2005-02       Impact factor: 4.307

2.  Safety, tolerability, and pharmacokinetics of 6-month daily dosing of an oral formulation of cyclosporine (ATOPICA for cats®) in cats.

Authors:  E S Roberts; K A Vanlare; G Strehlau; M Peyrou; L M Roycroft; S King
Journal:  J Vet Pharmacol Ther       Date:  2013-10-18       Impact factor: 1.786

3.  Dose tapering for ciclosporin in cats with nonflea-induced hypersensitivity dermatitis.

Authors:  Jean Steffan; Elizabeth Roberts; Andrea Cannon; Pascal Prélaud; Peter Forsythe; Jacques Fontaine; Stephen King; Wolfgang Seewald
Journal:  Vet Dermatol       Date:  2013-03-27       Impact factor: 1.589

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.